These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27070704)

  • 21. Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model.
    Hasan MN; Queudeville M; Trentin L; Eckhoff SM; Bronzini I; Palmi C; Barth T; Cazzaniga G; te Kronnie G; Debatin KM; Meyer LH
    Oncotarget; 2015 Jan; 6(3):1382-95. PubMed ID: 25682198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
    Einsiedel HG; Kawan L; Eckert C; Witt O; Fichtner I; Henze G; Seeger K
    Leukemia; 2006 Aug; 20(8):1435-6. PubMed ID: 16810202
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
    Paez-Ribes M; Man S; Xu P; Kerbel RS
    PLoS One; 2016; 11(6):e0158034. PubMed ID: 27355476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
    Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
    Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
    Pan CX; Zhang H; Tepper CG; Lin TY; Davis RR; Keck J; Ghosh PM; Gill P; Airhart S; Bult C; Gandara DR; Liu E; de Vere White RW
    PLoS One; 2015; 10(8):e0134346. PubMed ID: 26270481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Good engraftment of B-cell precursor ALL in NOD-SCID mice.
    Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J
    Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
    Suzuki K; Okuno Y; Kawashima N; Muramatsu H; Okuno T; Wang X; Kataoka S; Sekiya Y; Hamada M; Murakami N; Kojima D; Narita K; Narita A; Sakaguchi H; Sakaguchi K; Yoshida N; Nishio N; Hama A; Takahashi Y; Kudo K; Kato K; Kojima S
    J Clin Oncol; 2016 Oct; 34(28):3451-9. PubMed ID: 27507882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding.
    Belderbos ME; Koster T; Ausema B; Jacobs S; Sowdagar S; Zwart E; de Bont E; de Haan G; Bystrykh LV
    Blood; 2017 Jun; 129(24):3210-3220. PubMed ID: 28396495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.
    Sasaki T; Rivera-Mulia JC; Vera D; Zimmerman J; Das S; Padget M; Nakamichi N; Chang BH; Tyner J; Druker BJ; Weng AP; Civin CI; Eaves CJ; Gilbert DM
    Exp Hematol; 2017 Jul; 51():71-82.e3. PubMed ID: 28433605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
    Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
    Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
    Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
    Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
    Risbridger GP; Clark AK; Porter LH; Toivanen R; Bakshi A; Lister NL; Pook D; Pezaro CJ; Sandhu S; Keerthikumar S; Quezada Urban R; Papargiris M; Kraska J; Madsen HB; Wang H; Richards MG; Niranjan B; O'Dea S; Teng L; Wheelahan W; Li Z; Choo N; Ouyang JF; Thorne H; Devereux L; Hicks RJ; Sengupta S; Harewood L; Iddawala M; Azad AA; Goad J; Grummet J; Kourambas J; Kwan EM; Moon D; Murphy DG; Pedersen J; Clouston D; Norden S; Ryan A; Furic L; Goode DL; Frydenberg M; Lawrence MG; Taylor RA
    Nat Commun; 2021 Aug; 12(1):5049. PubMed ID: 34413304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.
    Uckun FM; Qazi S; Ma H; Reaman GH; Mitchell LG
    Integr Biol (Camb); 2015 Feb; 7(2):237-49. PubMed ID: 25567759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The future of patient-derived tumor xenografts in cancer treatment.
    Sia D; Moeini A; Labgaa I; Villanueva A
    Pharmacogenomics; 2015; 16(14):1671-83. PubMed ID: 26402657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.